(NEW YORK)–iBio, Inc. (NYSE: IBIO) stock rocketed after hours on news they were collaborating with Beijing CC-Pharming Ltd. to develop and test a new 2019-nCoV vaccine to be manufactured using iBio’s FastPharming System™. The companies are expediting work as predictions about spread of the disease continue to worsen.
The joint effort leverages twenty-five years of vaccine research and development experience – inclusive of work on the MERS-coronavirus – by Dr. Kevin Wang (Chairman and Chief Scientific Officer, CC-Pharming) along with the decades of experience that Dr. Sylvain Marcel (VP Upstream Bioprocessing, iBio) possesses in the rapid design of manufacturing processes for biopharmaceutical production in plant-based expression systems. If successful, the research will deliver product candidates which can then be quickly produced at iBio’s FastPharming Manufacturing Facility.
Originally built in 2010 with funding from the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense, iBio’s FastPharming Facility was part of the “Blue Angel” initiative to establish facilities capable of rapid delivery of medical countermeasures in response to a disease pandemic.
IBIO stock rallied up 58% after hours to around $0.43 per share.
Updates on Coronavirus Stocks
Register to get latest on the coronavirus outbreak and stocks related to this sector. Register to our investor network to get updates and alerts https://wallstreetnewscast.com/sectors/coronavirus/
iBio, Inc., is a global leader in plant-based biologics manufacturing. Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services via its 130,000 square foot facility in Bryan, Texas. iBio CDMO also enables innovators to use the FastPharming System for insourced manufacturing with Factory Solutions “design-and-build” services. Additionally, iBio’s FastGlycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. iBio is also developing proprietary products which include its lead asset, IBIO-100, for the treatment of fibrotic diseases. For more information, visit www.ibioinc.com
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. In Compliance with SEC Rule 17B WSNC was not compensated for this media alert. WSNC, or any of its affiliates, hold no positions in securities mentioned above. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial adviser before any and all investments.
Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial adviser before making any and all investment decisions when investing in these type of securities
- StoneMor (STON) Funeral Services Gains Interest from Traders - March 21, 2020
- OPKO Health (OPK) Scores Deal to Provide COVD-19 Tests in NYC - March 18, 2020
- S&P 500 Short-term Support May be Found at Weekly 200-day - March 12, 2020
- Pullback in Coronavirus Stocks Provide More Reasonable Entry Points - March 10, 2020
- OPKO Health (OPK) to Begin Testing on their Coronavirus Test Kits - March 8, 2020
- IBIO Rallies Sharply on Coronavirus Vaccine News - February 3, 2020
- Co-Diagnostics (CODX) Receives Upgrade on Development of Coronavirus Detection Test - January 31, 2020
- Data Elf Launches Online Network for AI and Data Science Programmers - January 20, 2020
- These Small Cap IoT Stocks Offer Real Upside Potential - December 3, 2019
- Orbsat (OSAT) Potential for Global IoT Data Provider Through Satellite Network - November 20, 2019